Balazs Halmos: The docetaxel enigma continues
Balazs Halmos, Associate Director for Clinical Science at Montefiore Einstein Cancer Center, shared a post by Bertrand Delsuc, CEO and Founder at Biotellytics, on X/Twitter, adding:
”Wow- the docetaxel enigma continues. Admittedly with a 20% or so RR in CEACAM5 high+ patients + ocular tox concerns, road did not seem easy for tusamitamab.”
Quoting Bertrand Delsuc’s post:
”SAN, SNY fail in 2L nsq NSCLC with their CEACAM5 ADC, no PFS improvement at final analysis vs docetaxel, trend only on OS. Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint. SAN, SNY apparently to change the linker-payload since saying they’ll continue to explore tusamitamab-based ADCs. View additional information.”
Source: Balazs Halmos/X and Bertrand Delsuc/X